Multimodal Theragnostic Anticancer Complexes of Rhenium to Circumvent Platinum Resistance in Relapsed Ovarian Cancer

Abstract

In this project, novel rhenium-based anticancer agents were explored as alternatives to the platinum drugs for the treatment of ovarian cancer. Over the course of this project, we explored the in vitro and in vivo anticancer activity of a range of different rhenium-based anticancer agents. We have shown that these compounds are highly effective in platinum-resistant ovarian cancer cells, suggesting that they may be valuable in this context. Furthermore, in vivo studies verified that these compounds are also effective in mice and appear to have minimal toxic side effects. Detailed mechanistic studies of these complexes show that they induce endoplasmic reticulum stress in ovarian cancer cells. This novel mechanism of action may be more broadly useful as a therapeutic strategy for the treatment of ovarian cancer. In summary, through this project we have identified a subset of rhenium complexes as promising anticancer agents for use in ovarian cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2020
Accession Number
AD1115893

Entities

People

  • Justin J. Wilson

Organizations

  • Cornell University

Tags

DTIC Thesaurus Topics

  • Animal Structures
  • Antineoplastic Agents
  • Body Weight
  • Cancer
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Detectors
  • Diseases And Disorders
  • Elements
  • Endoplasmic Reticulum
  • Metals
  • Neoplasms
  • Organelles
  • Side Effects
  • Transition Metals

Readers

  • Oncology (Cancer Research).